自己投与型自己免疫性注射剤の世界市場 (2028年まで)

治療用免疫調節剤の投与は、患者の健康や幸福に広く影響する疾患・適応症の増加により、医療の選択肢としてますます重要性を増してきています。しかし、このクラスの治療薬の価値を人体・収益の観点から十分に引き出すには、開発企業は薬剤の保管や投与に特有の問題をうまく切り抜け、投与経路を点滴から注射に移行させなければなりません。自己免疫などの慢性疾患を適応症とする抗体医薬は、しばしば注射剤に再製剤化、再包装、再ラベリングされ、市販後2～3年で再導入されます。これは、経済的圧力の高まりと自己注射を優先して外来点滴を必要としない患者の希望に対応するためです。

当レポートでは、世界の自己投与型自己免疫性注射剤の市場について分析し、製品の概略や現在の上市・開発状況、主な市場促進・抑制要因、主要企業のプロファイルと市場規模・シェア (2028年まで)、昨今の資本取引や技術/事業提携の動き、技術上・設計上・市場開拓上の課題、市場の主な背景事情 (経済的・技術的・規制的要因)、といった情報を取りまとめてお届けいたします。

目次

• エグゼクティブサマリー
• 自己投与自己免疫注射剤
• エグゼクティブサマリー
• 市場力学
• 競合情勢
• 医薬品のサプライチェーンの活動
• 製品設計と実現要因
• 使い易さ
• 患者のアドヒアランス
• 投与頻度
• 人間工学・エルゴノミクス
• 市販前・市販後のデバイスの進化
• 自己管理の実現装置
• デバイスの選択：安定性と材料の問題
• プレフィルドシリンジ
• 自動注射器
• Physioject (Becton Dickinson)
• Sensoready Pen
• Enbrel SureClick (Amgen)
• SmartJect (PA Consulting/Centocor)
• Pegasys Proclick (Genentech/Roche)
• 専用自動注射器
• ペン型注射器
• デュアルチャンバーペン
• 新たな装置
• 自己投与型・治療用の自己免疫薬
• Actemra (トシリズマブ)
• Benlysta (GSK/Human Genome Sciences)
• Betaseron
• Cosentyx
• Extavia
• Ilumya
• Kineret
• 腫瘍壊死因子
• Amjevita
• Benepali
• Enbrel (エタネルセプト)
• Halimatoz
• Hefiya
• Simponi (ゴリムマブ)
• 強直性脊椎炎
• クローン病
• 成人関節リウマチ
• 若年性特発性関節炎
• 多発性硬化症
• 乾癬性関節炎
• 潰瘍性大腸炎
• 市場要因
• 規制要因
• 治験のプロトコルと評価項目
• アライアンスとパートナーシップ
• 企業プロファイル

“Self-Administered Autoimmune Injectables to 2028” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing segment of the drug delivery sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of next generation injection devices on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Converging Factors Driving Self-administered Autoimmune Care

The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.

What You Will Learn:

• What approved drugs indicated for autoimmune conditions are marketed for self-administration, what is the as-supplied packaging, and who markets them?

• What are the major factors driving the migration of infusible drugs for treating autoimmunity to formulations that can be packaged and administered subcutaneously?

• What is the size of the market for self-administered autoimmune injectable drugs today, who are the market share leaders, and what will the market share be in 2028?

• How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?

• What are the essential design factors, technologies and market development issues for devices that can deliver injectable autoimmune drugs subcutaneously?

• What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?

Table of Contents

• Executive Summary
• Self-administered Autoimmune Injectables
• Executive Summary
• Market Dynamics
• Competitive Landscape
• Drug Supply Chain Activity
• Product Design and Enablement Factors
• Ease of Use
• Patient Adherence
• Dosing Frequency
• Human Engineering/Ergonomics
• Pre- and Post-Marketing Device Evolution
• Self-administered Enabling Devices
• Device Selection - Stability and Material Issues
• Prefilled Syringes
• Autoinjectors
• Physioject (Becton Dickinson)
• Sensoready Pen
• Enbrel SureClick (Amgen)
• SmartJect (PA Consulting/Centocor)
• Pegasys Proclick (Genentech/Roche)
• Special Feature Autoinjectors
• Pen Injectors
• Dual Chamber Pens
• Emerging Devices
• Self-administered Therapeutic Autoimmune Drugs
• Actemra (Tocilizumab)
• Benlysta (GSK/Human Genome Sciences)
• Betaseron
• Cosentyx
• Extavia
• Ilumya
• Kineret
• Tumor Necrosis Factors
• Amjevita
• Benepali
• Enbrel (Etanercept)
• Halimatoz
• Hefiya
• Simponi (Golimumab)
• Ankylosing Spondylitis
• Crohn's Disease
• Adult Rheumatoid Arthritis
• Juvenile Idiopathic Arthritis
• Multiple Sclerosis
• Psoriatic Arthritis
• Ulcerative Colitis
• Market Factors
• Regulatory Factors
• Clinical Trial Protocols & Endpoints
• Alliances and Partnerships
• Company Profiles